Bio-Techne Corporation

NasdaqGS:TECH 株式レポート

時価総額:US$12.4b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Bio-Techne マネジメント

マネジメント 基準チェック /24

Bio-Techne'sの CEO はKim Keldermanで、 Feb2024年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 2.61Mで、 22.6%給与と77.4%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.025%を直接所有しており、その価値は$ 2.89M 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と7.6年です。

主要情報

Kim Kelderman

最高経営責任者

US$6.9m

報酬総額

CEO給与比率11.1%
CEO在任期間less than a year
CEOの所有権0.03%
経営陣の平均在職期間1.1yrs
取締役会の平均在任期間7.7yrs

経営陣の近況

Recent updates

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Sep 26
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Sep 11
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

Aug 24
Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jun 09
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

May 21
Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Apr 30
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Apr 15
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30
Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Dec 05
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Oct 10
Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Sep 22
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Sep 01
A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jul 10
At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Jun 22
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Jun 07
With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

May 23
Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Apr 05
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Mar 21
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Mar 06
Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jan 03
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Dec 15
We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Nov 30
Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Nov 17
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne releases new AVV viral titer assays

Oct 11

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Sep 26
At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Sep 12
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Aug 29
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Bio-Techne releases Quantist Luminex data analysis software

Aug 18

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Aug 16
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

CEO報酬分析

Bio-Techne の収益と比較して、Kim Kelderman の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024US$7mUS$760k

US$168m

Mar 31 2024n/an/a

US$203m

Dec 31 2023n/an/a

US$224m

Sep 30 2023n/an/a

US$247m

Jun 30 2023US$3mUS$590k

US$285m

Mar 31 2023n/an/a

US$271m

Dec 31 2022n/an/a

US$262m

Sep 30 2022n/an/a

US$292m

Jun 30 2022US$3mUS$562k

US$272m

Mar 31 2022n/an/a

US$225m

Dec 31 2021n/an/a

US$210m

Sep 30 2021n/an/a

US$177m

Jun 30 2021US$4mUS$530k

US$140m

Mar 31 2021n/an/a

US$184m

Dec 31 2020n/an/a

US$175m

Sep 30 2020n/an/a

US$248m

Jun 30 2020US$2mUS$500k

US$229m

Mar 31 2020n/an/a

US$187m

Dec 31 2019n/an/a

US$195m

Sep 30 2019n/an/a

US$93m

Jun 30 2019US$2mUS$452k

US$96m

Mar 31 2019n/an/a

US$121m

Dec 31 2018n/an/a

US$96m

Sep 30 2018n/an/a

US$128m

Jun 30 2018US$2mUS$73k

US$126m

報酬と市場: Kimの 総報酬 ($USD 2.61M ) は、 US市場 ($USD 13.17M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Kimの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。


CEO(最高経営責任者

Kim Kelderman (57 yo)

less than a year

在職期間

US$6,852,495

報酬

Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Kim Kelderman
CEO, President & Directorless than a yearUS$6.85m0.025%
$ 3.1m
James Hippel
Executive VP of Finance & CFO10.4yrsUS$5.20m0.063%
$ 7.8m
Shane Bohnen
Senior VP1.5yrsUS$1.46m0.0011%
$ 131.3k
William Geist
President of Protein Sciences Segment2.7yrsUS$3.65m0.0028%
$ 346.8k
Matthew McManus
President of Diagnostics & Genomicsless than a yearUS$2.27mデータなし
Gary Latham
VP & CTOless than a yearデータなしデータなし
David Clair
Senior Director of Investor Relations & Corporate Developmentno dataデータなしデータなし
Gerry Andros
Vice President of Sales and Marketingno dataデータなしデータなし
Martin Wirtz
Senior Vice President of Strategy & Corporate Developmentless than a yearデータなしデータなし
Cheryl Bethune
Senior VP & Chief Human Resources Officerno dataデータなしデータなし
Luca Cicchetti
Managing Director8.2yrsデータなしデータなし
Steve Crouse
Senior Vice President of Analytical Solutions Division1.7yrsデータなしデータなし

1.1yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: TECHの経営陣は 経験豊富 とはみなされません ( 1.6年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
Kim Kelderman
CEO, President & Director1.7yrsUS$6.85m0.025%
$ 3.1m
Robert Baumgartner
Independent Chairman of the Board21.7yrsUS$410.46k0.027%
$ 3.4m
John Higgins
Independent Director15.3yrsUS$300.46k0.029%
$ 3.6m
Joseph Keegan
Independent Director7.7yrsUS$275.46k0.0078%
$ 961.1k
Randolph Steer
Independent Director34.7yrsUS$276.92k0.015%
$ 1.9m
Roeland Nusse
Independent Director14.3yrsUS$290.46k0.027%
$ 3.4m
Julie Bushman
Independent Director4.2yrsUS$291.50k0.0036%
$ 443.4k
John Denu
Member of Scientific Advisory Boardno dataデータなしデータなし
Sachdev Sidhu
Member of Scientific Advisory Boardno dataデータなしデータなし
S. J. Vessey
Independent Director5.3yrsUS$275.46k0.0050%
$ 615.6k
Alpna Seth
Independent Director7.7yrsUS$275.46k0.0078%
$ 961.1k
David Artis
Member of Scientific Advisory Boardno dataデータなしデータなし

7.7yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: TECHの 取締役会経験豊富 であると考えられます ( 7.6年の平均在任期間)。